Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on May 15, 2025
US Rare Cancer Market FDA Approved Rare Cancer Drug Clinical Trials Insight
GlobeNewswire
·
May 15, 2025
Delhi, May 15, 2025 (GLOBE NEWSWIRE) -- US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights: US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030 …
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 15, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter …
Kraig Biocraft Laboratories Receives Business License to Begin Operations in Cambodia
GlobeNewswire
·
May 15, 2025
ANN ARBOR, Mich., May 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today that it has officially received its business license to begin …
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 15, 2025
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to …
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to …
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging …
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
GlobeNewswire
·
May 15, 2025
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating …
EDAP Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled …
Axovia Therapeutics Unveils New Preclinical Data for AXV-201, for Treatment of Genetic Obesity Caused by MC4R Mutations, at ASGCT
GlobeNewswire
·
May 15, 2025
LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced that today it will unveil new preclinical proof-of-concept data for novelly …
SBC Medical Group Holdings Announces Approval of Share Repurchase Program and Commencement of Share Repurchases
GlobeNewswire
·
May 15, 2025
IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings (Nasdaq: SBC, “the Company”) today announces that its Board of Directors has approved the following share repurchase program and will commence repurchasing its own shares as early …
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer
GlobeNewswire
·
May 15, 2025
Two independent Phase 2 trials demonstrate extended progression-free survival in patients without TP53 mutations or without liver metastases Results presented at 2025 ESMO Breast Cancer Annual Congress BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Carrick …
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
GlobeNewswire
·
May 15, 2025
– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. …
QHSLab, Inc. Reports 32% Year-Over-Year Revenue Growth and Expanded Gross Margins in First Quarter 2025
GlobeNewswire
·
May 15, 2025
Revenue increased 32% year-over-year to $645,419, driven by growth in ISP and Allergy Diagnostics Gross margin expanded to 66.6%, reflecting improved product mix and operational efficiencies WEST PALM BEACH, FL, May 15, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. …
AAFA Calls for Comprehensive Reform to Make Medicines Accessible and Affordable for All
GlobeNewswire
·
May 15, 2025
Washington, DC, May 15, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) appreciates the President’s Executive Order calling attention to America’s persistent problem of unaffordable prescription medicines. Our research tells us …
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 15, 2025
Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progress New givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, Spain Strong financial position supported by …
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
GlobeNewswire
·
May 15, 2025
FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” Additional briefing document in support …
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 15, 2025
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to …
Venus Concept Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial …
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
GlobeNewswire
·
May 15, 2025
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of …